Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26155923 | 0.92 | PNP (0.73) | PNPKDM4EMEN1ALDH1A1MAPT | |
| Trifluoroacetic Acid SCHEMBL2300171 | 0.86 | PNP (0.54) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL26155922 | 0.85 | PNP (0.48) | PNPKDM4EMEN1ALDH1A1MAPT | |
| 8-Aminoguanine SCHEMBL21761 | 0.85 | PNP (1.00) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL10597942 | 0.78 | PNP (0.70) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3291323 | 0.76 | NUDT1 (0.44) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL843932 | 0.76 | PNP (0.73) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL20577 | 0.76 | PNP (0.73) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL844207 | 0.76 | PNP (0.73) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6686388 | 0.76 | PNP (0.73) | PNPKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6845 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026099790-A1 | DEVICE USING ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099316-A1 | COMPOUNDS AND METHODS FOR REDUCING ARHGEF6 EXPRESSION | ASTRAZENECA AB (SE) | 2026-05-15 | — | — | WO | claimed |
| US-20260131157-A1 | METHODS OF USING ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-05-14 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-12569572-B2 | Messenger RNA therapy for the treatment of Friedreich's ataxia | TRANSLATE BIO, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| EP-4452256-B1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2025-12-10 | — | — | EP | claimed |
| US-12473663-B2 | Compositions and methods for immune repertoiresequencing | Life Technologies Corporation (US) | 2025-11-18 | — | — | US | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | claimed |
| US-5386030-A | Chemical intermediates | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) | 1995-01-31 | — | — | US | claimed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | claimed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | claimed |
| EP-0625985-A1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES. | UNIV MIAMI (US) | 1994-11-30 | — | — | EP | claimed |
| WO-1993011146-A1 | METHOD AND RING-OPENED PURINE COMPOUNDS FOR LABELING POLYNUCLEOTIDES | UNIVERSITY OF MIAMI (US) | 1993-06-10 | — | — | WO | claimed |
| EP-0540693-A1 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING $i(IN VITRO) NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1993-05-12 | — | — | EP | claimed |
| US-5208221-A | Nucleotides and intermediates for herpes virus or leukemia virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-04 | — | — | US | claimed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | claimed |
| WO-1992001814-A2 | THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING IN VITRO NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES | F. HOFFMANN-LA-ROCHE AG (CH) | 1992-02-06 | — | — | WO | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |